Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children

21 juli 2014 uppdaterad av: MedImmune LLC

A Post Marketing Evaluation of the Effectiveness of the Risk Minimization Plan For Use of FluMist Among Children Less Than 5 Years of Age

This is a retrospective cohort study of children included in a large medical insurance claims database.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

  • To evaluate the rate of FluMist administration compared to other influenza vaccine use in the following pediatric populations:

    • Children younger than 24 months of age
    • Children 24-59 months of age with a claim associated with a diagnosis of asthma
    • Children 24-59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
    • Children 24-59 months of age with immunosuppression
  • To describe, in children in the above populations who receive FluMist, the type and number of Emergency Room visits or hospitalizations associated with an insurance claim within 42 days of receiving FluMist
  • To explore the rationale for FluMist immunization of pediatric populations that are excluded from recommended usage by characterizing the use in these populations

Studietyp

Observationell

Inskrivning (Faktisk)

321697

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • North Carolina
      • Research Triangle, North Carolina, Förenta staterna
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Children < 60 months of age.

Beskrivning

  • Children less than 24 months of age during August through January/February.
  • Children <24 to 59 months of age during August through January/February, with:

    • two outpatient claims for asthma, or
    • one inpatient/emergency room claim for asthma, or
    • one outpatient claim for asthma and at least one SABA prescription during a defined 12-month period.
  • Children <24 to 59 months of age during August through January/February, without any claims associated with a diagnosis of asthma, but with at least one dispensing for SABA, as indicated by pharmacy claims during a defined 12-month period.
  • Children 24 to 59 months of age during August to January/February with evidence of immunosuppression prior to the date of influenza vaccination based on available medical and pharmacy claims.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Kohort
  • Tidsperspektiv: Retrospektiv

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
1
Children less than 24 months of age
There were no interventions. No subjects were enrolled in this retrospective database study.
2
Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
There were no interventions. No subjects were enrolled in this retrospective database study.
3
Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
There were no interventions. No subjects were enrolled in this retrospective database study.
4
Children 24-59 months of age with immunosuppression
There were no interventions. No subjects were enrolled in this retrospective database study.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
FluMist Use in Participants up to 59 Months of Age
Tidsram: 2009-2010
Among participants up to 59 months of age who received any flu vaccine, number who received FluMist
2009-2010
Vaccinating Physician Specialty: Pediatrician or Pediatric Specialist
Tidsram: 2009-2010
Specialty of vaccinating physician who provided FluMist.
2009-2010
Vaccinating Physician Specialty: General/Family Practitioner
Tidsram: 2009-2010
Specialty of vaccinating physician who provided FluMist
2009-2010
Vaccinating Physician Specialty: Other
Tidsram: 2009-2010
Specialty of vaccinating physician who provided FluMist
2009-2010
Vaccinating Physician Specialty: Unknown
Tidsram: 2009-2010
Specialty of vaccinating physician who provided FluMist
2009-2010
Geographic Region: Northeastern
Tidsram: 2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Geographic Region: North Central
Tidsram: 2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Geographic Region: Southern
Tidsram: 2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Geographic Region: Western
Tidsram: 2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Number of Outpatient Visits: 0
Tidsram: 2009-2010
Among participants vaccinated with FluMist, the number who had 0 outpatient visits in the 3 months prior to vaccination
2009-2010
Number of Outpatient Visits: 1
Tidsram: 2009-2010
Among participants vaccinated with FluMist, the number who had 1 outpatient visit in the 3 months prior to vaccination
2009-2010
Number of Outpatient Visits: 2 or More
Tidsram: 2009-2010
Among participants vaccinated with FluMist, the number who had 2 or more outpatient visits in the 3 months prior to vaccination
2009-2010
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 0
Tidsram: 2009-2010
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
2009-2010
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 1
Tidsram: 2009-2010
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
2009-2010
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 2 or More
Tidsram: 2009-2010
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
2009-2010

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Utredare

  • Studierektor: Chris Ambrose, M.D., MedImmune LLC

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 oktober 2007

Primärt slutförande (Faktisk)

1 mars 2010

Avslutad studie (Faktisk)

1 mars 2010

Studieregistreringsdatum

Först inskickad

20 februari 2008

Först inskickad som uppfyllde QC-kriterierna

20 februari 2008

Första postat (Uppskatta)

29 februari 2008

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

12 augusti 2014

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 juli 2014

Senast verifierad

1 juli 2014

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • MI-MA175

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera